Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.
Henry Ng, Sebastian Havervall, Axel Rosell...
https://pubmed.ncbi.nlm.nih.gov/33267662Actively Recruiting
Age: 18Years +
All Genders
Healthy Volunteers
ID06784739
COMMUNITY - the COVID-19 Immunity Study
Led by Danderyd Hospital · Updated on 2025-01-20
5500
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating immune responses to SARS-CoV-2 infection and vaccination in healthcare workers and hospitalized COVID-19 patients. The study includes a total of 5,000 healthcare workers and 500 COVID-19 patients enrolled at Danderyd Hospital in Stockholm, Sweden. It aims to understand antibody and cellular immune responses over time to SARS-CoV-2 and other respiratory viruses like Influenza A/B and RSV. Participants undergo regular follow-ups every four months, where blood and mucosal samples (saliva and nasal secretions) are collected. Sub-studies include more frequent sampling and PCR testing for respiratory infections regardless of symptoms. Data on infection and vaccination history are gathered from national registries, and participants provide clinical and demographic information via a smartphone app. Throughout the study, researchers measure antibody and cellular immune responses, detect viral infections using PCR, and evaluate the mucosal microbiome. Samples are stored in a biobank for future analysis. Participants are monitored until 2027, with ongoing data collection and occasional PCR screenings to track infections and vaccine responses.
CONDITIONS
Brief Title
COMMUNITY - the COVID-19 Immunity Study
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Health care workers employed at Danderyd Hospital at time of enrollment
- Patients admitted to Danderyd Hospital with confirmed SARS-CoV-2 infection at time of enrollment
- Adults aged 18 years and older
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - Ongoing throughout study participation
Participants undergo PCR testing to detect infections with SARS-CoV-2, Influenza A/B, and RSV A/B.
Long-term Monitoring
Duration - Up to 5 years
Participants are followed longitudinally with blood and mucosal sampling to assess immune responses and collect clinical and demographic data through a smartphone app system.
Follow-ups every 4 months
Trial Site Locations
Total: 2 locations
1
Danderyd hospital
Stockholm, Sweden, 18288
Actively Recruiting
2
Karolinska Institutet Danderyd Hospital
Stockholm, Sweden, 18288
Actively Recruiting
Loading map...
Research Team
N
Nina Greilert Norin, RN
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Tissue factor activity of small and large extracellular vesicles in different diseases.
Ana T A Sachetto, Sierra J Archibald, Yohei Hisada...
https://pubmed.ncbi.nlm.nih.gov/37012986Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.
Vanessa Monteil, Brett Eaton, Elena Postnikova...
https://pubmed.ncbi.nlm.nih.gov/35781796A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies.
Sara Mravinacova, Malin Jönsson, Wanda Christ...
https://pubmed.ncbi.nlm.nih.gov/34628049SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.
Sebastian Havervall, August Jernbom Falk, Jonas Klingström...
https://pubmed.ncbi.nlm.nih.gov/35020778Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al.
Fien A von Meijenfeldt, Sebastian Havervall, Jelle Adelmeijer...
https://pubmed.ncbi.nlm.nih.gov/34731533Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden.
Kim Blom, Oscar Bladh, Sebastian Havervall...
https://pubmed.ncbi.nlm.nih.gov/37680234Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge.
Fien A von Meijenfeldt, Sebastian Havervall, Jelle Adelmeijer...
https://pubmed.ncbi.nlm.nih.gov/33560386Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers.
Sebastian Havervall, Axel Rosell, Mia Phillipson...
https://pubmed.ncbi.nlm.nih.gov/33825846Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.
Kim Blom, Ulrika Marking, Sebastian Havervall...
https://pubmed.ncbi.nlm.nih.gov/35691303